**Curriculum Vitae**

**KYRIAKI THERMOS (Κ. ΘΕΡΜΟΥ)**

***Kyriaki Thermos*** is Professor and Chairman of Pharmacology, School of Medicine, University of Crete. She received her BSc. degree in Chemistry (1976) from the Department of Chemistry, University of Patras, Greece, MSc. in Chemistry (1979) and Ph.D in Neurochemistry (1984) from the Department of Chemistry, New York University, N.Y., USA. She trained as a postdoctoral fellow in the Training Program of Neuropsychopharmacology, University of Pennsylvania, School of Medicine, NIMH-MH 146554 (1984-1986) and in parallel collaborated with the Department of Pharmacology, Medical College of Pennsylvania (MCP, Prof. Benjamin Weiss). Instructor in Pharmacology (MCP, Jan 1986-June 1986). She held the position of postdoctoral fellow/ Instructor of Pharmacology in the Department of Pharmacology, University of Pennsylvania, School of Medicine (Prof. T. Reisine, Sept 1986 - May 1988), Assistant Professor (1988), Associate Professor (1993) and Professor of Pharmacology (2009) at the School of Medicine, University of Crete. She served as the Chairman of the Department of Basic Sciences and Member of the Executive Council of the School of Medicine, University of Crete (1996-1997), Vice-Director of the Laboratory of Clinical Pharmacology, University Hospital (1990-2000, 2002-2008) and Director (2000-2002, 2008-present), Scientific Collaborator (2000-2010) and Member of the Secondary Executive Council (2001-2005) of the National Organization for Medicines, Executive Committee Member (1993-present), Associate Director (2001- 2011, 2014-2018) and Director (2011-2014, 2018-present) of the Graduate Program in Neuroscience, School of Medicine, University of Crete. She served as member of the Executive Committee of the Hellenic Society for the Neurosciences (1989-1992), its representative to the International Brain Research Organization (**IBRO,** member of **Governing Council**, 2000-2006), **President** (2001-2003) and **General Secretary** (2003-2005) of the **Greek Pharmacological Society**. She served as a member of the **Network of European Neuroscience Schools** (NENS, 2003-2005), as a member (2009-2012) and **Chair** (July 2012- July 2014) of the **Communication Committee of the Federation of European Neuroscience Societies (FENS)** and **member** of the **Executive Committee of FENS** (July 2012- July 2014). She served as a member of the 1st Council of the University of Crete (2012-2017).

***Science Biography***

The focus of Dr. Thermos' research the past 15 years has been the investigation of new targets for drug development and new therapeutics for retinal disease. She studied the neurobiology/neuropharmacology of different biological systems and their function in retinal circuitry focusing on the somatostatin, NO/cGMP, endocannabinoid and neurosteroidal microneurotrophin systems. In parallel, she examined the putative neuroprotective/ therapeutic effects of the above mentioned agents in ischemia induced retinopathies. She has employed ex vivo (chemical ischemia), in vivo (AMPA excitotoxicity) and disease (diabetic retinopathy) models for her studies. Investigation of the endocannabinoid system and NADPH Oxidase (NOX) inhibitors as therapeutic targets is presently at the forefront of her research interests. In parallel to the studies in the retina, initially used as a model of the CNS, she investigated the role of somatostatin and its receptors in brain function and disease.

***Teaching Experience***

Since 1988, she has been teaching Medical Pharmacology, Cell Communication and Signalling (elective) to medical students at the Faculty of Medicine, University of Crete. She has taught in many Graduate Programs. Worth mentioning is her contribution to the development and organization of the Graduate Program of Neuroscience, Faculty of Medicine University of Crete, the first graduate program of Neuroscience in Greece. She organized and taught courses such as: Special Topics in Neuropharmacology, Neurochemistry/Neuropharmacology, and topics in the Core courses in Neuroscience. She has supervised 4 Postdoctoral Fellows, 13 PhD students (two of which have obtained Faculty positions in Greek Universities after successful postdoctoral fellowships in Europe and USA), 14 MSc students, and many undergraduate theses.

***Awards***

Fellowship for graduate studies (MSc and Ph.D) at New York University (1977-1984), Fellow, Training Program in Neuropsychopharmacology, University of Pennsylvania, School of Medicine, NIMH-MH 146554 (1984-1986), Biomedical Research Service Award, Medical College of Pennsylvania and Eastern Pennsylvanian Psychiatric Institute, Philadelphia, USA (1986-1987).

***Funding (up to 2000)***

***As a postdoctoral fellow:*** “Studies of sites involved in dopaminergic supersensitivity”**,** National Institute of Mental Health (NIMH-42015-01 **R03;** $15000) (1986-1987, **PI**)**.**

***As a Faculty Member - UoC***

“Dopamine-somatostatin interactions: changes after chronic administration of antidepressant drugs. Pharmacological approach to the neurobiological substrate of depression”, Greek Ministry of Health (1989-1991, **PI),** “Study of somatostatin receptors. Solubilization and reconstitution in a superficial membrane”, University of Crete, Research Account (1989-1992, **PI**)**,** “Study of pharmacological characteristics of dopamine receptor subtypes: New therapeutic targets for neuropsychiatric diseases”, Greek Ministry of Health (1991-1992)**, “**Pharmacological and molecular characterization of somatostatin receptors”, Greek Ministry of Health (1991-1992, **PI**)**,** “Characterization of somatostatin receptors in the brain: Study of dopamine-somatostatin interactions”**,** Greek Drug Association (1991-1992, **PI**)**,** “Interactions of somatostatin with other neurotransmitter systems in the central nervous system: Projections of the role of somatostatin in the pathogenesis of CNS disorders”, General Secretariat-Ministry of Research and Development/PENED (1991-1993, **PI**)**,** “Determination of somatostatin release in the nucleus accumbens: effect of chronic antidepressant treatment”. General Secretariat-Ministry of Research and development/PENED (1996-1998, **PI**)**,** “Biology of Cancer: Genetic Analysis and in vivo imaging of receptors-radiotherapy”**,** General Secretariat-Ministry of Research and development, EPET II (1998-2000)**,** “Study of the role of somatostatin in the neuronal circuits of the retina”, General Secretariat-Ministry of Research and development, France-Greece Collaboration (In collaboration with Dr J. Epelbaum, Centre Paul Broca, Paris) (1998-2001, **PI**)**,** “Study of the role of somatostatin in the neuronal circuits of the retina”, University of Crete, Research Account (1998-2000, **PI**)**.**

**Funding after 2000: List of Research Projects, title, budget, source, role in research team, starting/ending dates**  
1. Title: Somatostatin and its Receptors in Brain Function and Dysfunction. Budget: 209.325,34 €, Source: European Commission Contract, 5th Framework (QLG3-CT-1999-00908), Role: Co-Investigator. *Duration: 1/1/2000 -31/12/2003.*2. Title: Study of the role of somatostatin as a neuroprotectant in ischemic retinophathies: Somatostatin-Nitric Oxide and glutamic acid interaction is the retina. Budget: 34.403,00 €, Source: NOVARTIS, BASEL Role: **Principal Investigator,** Duration:*1/1/2002-31/12/2005.*3. Title: Synthesis and pharmacological study of new cannabinoids with putative analgesic and psychomotor actions without addictive effects. Budget: 100.420,00, € Source: General Secretariat of Research and Technology (Program EPAN).Role:Co-Investigator.Duration:*15/9/2003-15/7/200.*4. Title: Functional mapping of somatostatin receptors in the basal ganglia. Study of the interactions of somatostatin with other neurotransmitter systems” Budget: 33.421,97€, Source: Ministry of Education (Program Heraklitus).   
Role: P**rincipal Investigator**. *Duration:8/11/2002-15/6/2007.*5. Title: Study of the role of somatostatin in the treatment of diseases such as retinal ischemia and hepatocellular carcinoma” Budget: 85.000,00 €, Source: Ministry of Education (Program Pythagoras), Role: **Principal Investigator**. Duration:1/3/2004-31/8/2008.  
6. Title: Experimental models of retinopathies and the role of somatostatin as a neuroprotectant” Budget: 56.250,00 €, Source: General Secretariat-Ministry of Research and Technology (Program PENED), Role: **Principal Investigator.** *Duration:12/12/2005-30/6/2009.*7. Title: Somatostatin analogues as therapeutic targets in ischemia induced retinopathies” Budget: 2.500,00 €, Source: University of Crete Research Committee Role: **Principal Investigator**. *Duration: 20/5/2011 - 19/5/2012.*8. Title: Study of the neuroprotective actions of cannabinoids against retinal ischemia” Budget: 45.000,00 € Source: Ministry of Education (Program Heraklitus II-Support for Ph.D student D. Kokona).   
Role: **Principal Investigator**. *Duration:16/2/2011-16/2/2014.  
9.* Title: Study of new therapeutic targets for the treatment of diabetic retinopathy: Neurosteroids/Microneurotrophins. Budget: 210.000,00 €, Source:ESPA/ Γ.Γ.Ε.Τ (ARISTEIA II), Role: **Principal Investigator**. *Duration: 31/01/2014-31/10/2015.  
10.* Title: Investigation of the down-regulation of the CB1 cannabinoid receptor in the retina and its implication in the therapeutic properties of endocannabinoids and synthetic cannabinoids in retinal disease. Budget: 3.500,00 €, Source: University of Crete Research Committee, Role: **Principal Investigator***, Duration:*01/04/2017-31/10/2017.

11. Title: Investigation of new therapeutic targets for the treatment of diabetic retinopathy: neurosteroidal microneurotrophins, Budget: 15.000,00 €, Source: University of Crete Research Committee, Role:**Principal Investigator,***Duration:*10/09/2015-09/09/2017.  
*12.* Title Study of the effect of chronic administration of endogenous and synthetic cannabinoids in the function of the cannabinoid receptor -1 (CB1) in healthy retina and in an experimental model of retinopathy. Budget: 22.500,00€, Source: ELIDEK (Support for Ph.D student Sofia Papadogkonaki), Role: **Principal Investigator**, Duration: 1/11/2017-30/04/2020. *13.* Title: ULTRACHIRAL - Ultrasensitive chiral detectioin by signal - reversing cavity polarimetry, Budget: UoC-MED 218 886.00€ (Thermos,50k), Source: Horizon 2020, Role: **Co-Investigator**, *Duration:* 09/03/2017-31/12/2020.

**PUBLICATIONS (\*corresponding author)**

**1. Thermos, K**., Murphy, R. B., and Schuster, D. I. Photoincorporation of [3H]Chlorpromazine into a solubilized bovine striatal preparation. ***Biochemical Biophysical Research Communications*** 106:1469-1477, 1982.   
2. Schuster, D.I., Murphy, R.B., Ashton, R., **Thermos, K.,** Wennogle, L.P., Meyerson, L.R. *"Photolabeling of neurotransmitter receptor sites in the brain."* ***American Chemical Society Symposium Series***  278:125-146, 1985.   
3. **Thermos, K**., Winkler, J.D. and Weiss, B. Effects of the irreversible dopaminergic ligand fluphenazine-N-mustard on dopaminergic behavior in supersensitive mice. ***Neuropharmacology*** 26: 1473-1480, 1987.   
4. Winkler, J.D., **Thermos, K.,** and Weiss, B. Differential Effects of fluphenazine-N-mustard on calmodulin activity and D1 and D2 dopaminergic responses. ***Psychopharmacology*** 92: 285-291, 1987.   
5. **Thermos, K.** and Reisine, T. Molecular mechanisms regulating ACTH synthesis and release. ***Annals of New York Academy Sciences*** 512: 187-194, 1987.   
6. Katerinopoulos, H., **Thermos, K.,** Vassilatis, D., Schuster, D.I.Synthesis and dopamine receptor binding of rigid dopamine analogs. ***European Journal Medicinal Chemistry*** 23: 391-396, 1988.   
7. Mahy, N., Woolkalis, M., **Thermos, K.,** Carlson, K., Manning, D., Reisine, T. Pertussis toxin modifies the characteristics of both the inhibitory GTP binding proteins and the somatostatin receptor in anterior pituitary tumor cells. ***Journal of Pharmacology and Experimental Therapeutics*** 246:779-785, 1988.   
8. **Thermos, K.** and Reisine, T. Somatostatin receptor subtypes in the clonal anterior pituitary cell lines AtT-20 and GH3. ***Molecular Pharmacology*** 33: 370-377, 1988.   
9. He, H-T., Johnson, K., **Thermos, K.** and Reisine, T. Purification of a putative brain somatostatin receptor. ***Proceedings National Academy Science (PNAS-USA****)* 86: 1480-1484, 1989.   
10. **Thermos, K.,** He, H-T., Wang, H-L., Margolis, N., Reisine, T. Biochemical properties of brain somatostatin receptors. ***Neuroscience***31: 131-141, 1989.   
11. Katerinopoulos, H. and **Thermos, K.** Synthesis and dopaminergic properties of bridged tricyclic dopamine analogues. ***European Journal Medicinal Chemistry***  24: 615-617, 1989.   
12. Reisine, T., He, H-T., Rens-Damiano, S., Raynor, K., Borislow, S., and **Thermos, K.** Biochemical properties of somatostatin receptors. ***Metabolism*** 39: 70-73, 1990.   
13. **Thermos, K.,** Meglasson, M.D., Nelson, J., Smith, K.M., and Reisine, T. Pancreatic beta cell somatostatin receptors. ***American Journal of Physiology*** 259: E216-E224, 1990.   
14. Liapakis, G. and **Thermos, K\*.** Characterization of [125I]Tyr11-Somatostatin binding in the Retina. ***Neuropeptides*** *21*: 13-19, 1992.   
15. Georvasaki, E., **Thermos, K\*.,** Liapakis, G., Spyraki, C. Effect of acute and chronic treatment of desipramine on somatostatin receptors in brain. ***Psychopharmacology*** 108: 363-366, 1992.   
16. Kouvarakis, A., **Thermos, K.** Hieble, P. and Katerinopoulos, H.E. Synthesis of rigid catecholamine analogues: Effects on dopaminergic and adrenergic systems. ***European Journal Medicinal Chemistry*** 28: 251-256, 1993.   
17. Liapakis, G., Politou, E. and **Thermos, K\*.** Characterization of somatostatin receptors in rabbit retina. ***Biochemical Pharmacology*** 45:1821-1828, 1993.   
18. Radke, J., Spyraki, C., and **Thermos, K\*.** Measurement of extracellular somatostatin levels in the striatum using in vivo intracerebral microdialysis. ***Neuroscience*** 54: 493-498,1993.   
19. Hatzoglou, A., Ouafik, L’H., Bakogeorgiou, E., **Thermos, K.** and Castanas, E. Morphine cross-reacts with somatostatin receptors in the T47D human breast cancer cell line. ***Cancer Research*** 55: 5632-5636, 1995.   
20. Katerinopoulos, H.E., Tagmatarhis, N., Zaponakis, G. and **Thermos, K**. Conformationally flexible analogs of Abbot-68930 studies on dopaminergic and -adrenergic activity. ***European Journal Medicinal Chemistry*** 30:949-954, 1995.   
21. **Thermos, K\*.,** Radke, J., Kastellakis, A., Anagnostakis, Y. and Spyraki, C. Dopamine-somatostatin interactions in the rat striatum. ***Synapse***22: 209-216, 1996.   
22. Kouroumalis, E.A., Skordilis, P., **Thermos, K.,** Vasilaki, A., Moschandrea, J. and Manousos, O.N. Treatment of hepatocellular carcinoma with octreotide: a randomized study. ***Gut*** 42: 442-447, 1998.   
23. Tagmatarhis, N., **Thermos, K.** and Katerinopoulos, H. N-Iodopropenyl-octahydrobenzo[f]-and [g]Quinoline analogs with adrenergic and dopaminergic activity. ***Journal Medicinal Chemistry*** 41: 4165-70, 1998.   
24. Tzanakis, N., Metzidaki, G., **Thermos, K.,** Spyraki, C., Bouros, D. Anaphylactic shock after a single oral dose of acetazolamide. ***British Journal of Ophthalmology*** 82: 588, 1998.

25. Mehta, A., **Thermos, K.** and Chesselet, M.F. Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus following nigrostriatal lesion. ***Synapse*** 37: 298-307, 2000.   
26. Vasilaki, A., Gardette, R., Epelbaum, J. and **Thermos, K.\*** NADPH-diaphorase colocalizes with somatostatin receptor subtypes sst2A and sst2B in the rat and rabbit retina. ***Investigative Ophthalmology and Visual Science***  42: 1600-1609, 2001.   
27. **Thermos, K.,** Froudakis, G.E., Tagmatarchis, N. and Katerinopoulos H.E. cis-and trans-N-benzyl-octahydrobenzo[g]quinolines. Adrenergic and dopaminergic activity studies. ***Bioοrganic Medicinal Chemistry Letters*** 11:883-886, 2001.   
28. Pallis, E., **Thermos, K.\*** and Spyraki, C. Chronic desipramine treatment potentiates the somatostatin induced dopamine release selectively in the nucleus accumbens. ***European Journal Neuroscience*** 14: 763-767, 2001.   
29. Vasilaki, A., Mouratidou, M., Schulz, S., **Thermos, K.\*** Somatostatin influences nitric oxide production in the rat retina. ***Neuropharmacology*** 43: 899-909, 2002.   
30. Grigoryan, E., Vasilaki, A., Mastrodimou, N. and **Thermos, K.\*** Somatostatin receptor immunoreactivity in the eye of the adult newt (pleurodeles waltli) ***Neuroscience Letters*** 337: 143-146, 2003.   
31. Vasilaki, A., Georgousi, Z., and **Thermos, K. \*** Somatostatin receptors (sst2) are coupled to Go and modulate GTPase activity in the rabbit retina. ***Journal of Neurochemistry*** 84:625-632, 2003.   
32. **Thermos K.** Functional mapping of somatostatin receptors in the retina: A review***Vision Research*** 43: 1805-1815, 2003.   
33. Papadaki, Τ, Tsilibaris, Μ., **Thermos, K**., Karavellas, M.P., Samonakis, D., Papadakis, A., Linardakis, M., Pallikaris, I. The role of lanreotide in the treatment of choroidal neovascularization secondary to age related macular degeneration: a pilot clinical study **Retina** 26: 800-807, 2003.   
34. Mastrodimou, N. and **Thermos, K**\*. The Somatostatin receptor (sst1) modulates the release of somatostatin in rat retina. **Neuroscience Letters** 356: 13-16, 2004.   
35. George Notas, George Kolios, Niki Mastrodimou, Marilena Kampa, Anna Vasilaki, Costas Xidakis, Elias Castanas, **Kyriaki Thermos**, Elias Kouroumalis. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors **J. Hepatology** 40:792-798,2004.  
36. Vasilaki, A., Papadaki, T., Notas, G., Kolios, G., Mastrodimou, N., Hoyer, D, Tsilimbaris, M., Kouroumalis, E., Pallikaris, I. and **Thermos, K\*.** Somatostatin regulates nitric oxide production in human retinal pigment epithelium (RPE) cell cultures ***Investigative Ophthalmology & Visual Science*** *45:*1499-506, 2004.   
37. Vasilaki, Α., Papasava, D., Hoyer, D., and **Thermos, K\*.** Somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens. **Neuropharmacology** 47: 612-618, 2004.   
38. Mastrodimou, N., Lambrou, G., and **Thermos, K.\*** Effect of somatostatin, cortistatin and sst2 agonists on chemically induced ischemia in rat retina. **Naunyn-Schmiedeberg’s Archives of Pharmacology** 371: 44-53, 2005.   
39. Marazioti, A., Kastellakis, A., Antoniou, K., Papasava, D., **Thermos, K.\***Somatostatin and analogs administered in the ventral pallidum decrease locomotor activity of rats. **Psychopharmacology** 181: 319-326, 2005.   
40. Antoniou K., Galanopoulos A., Vlachou S., Kourouli T., Nahmias V., **Thermos, K**., Panagis G., Daifoti Z., Marselos M.., Papahatjis D., and Spyraki C. Behavioral pharmacological properties of a novel cannabinoid 1’,1’-dithiolane Δ8-THC analogue, AMG-3. **Behavioral Pharmacology** 16: 499-510, 2005.   
41. Kouvidi, E., Daifoti, Z. and **Thermos, K\*.** Somatostatin receptors (sst1 and sst2) modulate dopamine release in the rat retina. **Neuroscience Letters** 391:82-86, 2006.   
42. Mastrodimou, N., Kiagiadaki, F., Hodjarova, M., Karagiani, E and **Thermos, K.\*** Somatostatin modulates cGMP levels in the rat retina. Involvement of nitric oxide synthase. **Regulatory Peptides** 133: 41-46, 2006.   
43. Pallis, E., Spyraki, C., **Thermos, K.\*** Chronic antidepressant treatment modulates the release of somatostatin in the nucleus accumbens of the rat **Neuroscience Letters** 395: 76-81, 2006.   
44. **Thermos, K.,** Bagnoli, P., Epelbaum, J., Hoyer, D. The somatostatin sst1 receptor: An autoreceptor for somatostatinin brain and retina? **Pharmacology and Therapeutics** 110: 455-464, 2006   
45. Mastrodimou, N., Vasilaki, A., Papadioti, A., Low, M., Hoyer, D. and **Thermos, K.\*** Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology. Neuropeptides,40:365-373, 2006.   
46. Notas, G., Kampa, M., Nifli, A.-P., Xidakis, K., Papasava, D., **Thermos, K**., Kouroumalis, E. And Castanas, E. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. **European Journal of Pharmacology**, 555: 1-7, 2007.   
47. Xidakis, K., Mastrodimou, N., Notas, G., Renieri E., Kolios, G., Kouroumalis, E., **Thermos, K.**\*RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. **Regulatory Peptides** 143: 76-82, 2007.  
48. Konstandi, M., Harkitis,P., **Thermos, K.,** Johnson, E.O., Tzimas, P., Marselos,M. Short-term exposure to benzo (α) pyrene modifies brain and drug induced dopaminergic activity. **Neurotoxicology** 28: 860-867, 2007.   
49. Kiagiadaki, F., Koulakis, E., **Thermos , K**\*. Dopamine via D1 receptor activation and cGMP modulate somatostatin release in the rat retina.  **Experimental Eye Research** 86:18-24, 2008.  
50. Mastrodimou, N., Kiagiadaki, F., **Thermos, K**\*. The role of nitric oxide and cGMP in somatostatin’s protection of retinal ischemia**. Investigative Ophthalmology Visual Science** 49: 342-249, 2008.   
51. **Thermos, K**\***.** Novel signals mediating the function of somatostatin: the emerging role of NO/cGMP. **Molecular and Cellular Endocrinology (invited review, Special Issue on Somatostatin and Cortistatin)** 286:49-57, 2008.   
52. Kiagadaki, F. and **Thermos, K**\*. Intravitreal administration of somatostatin and sst2 analogs protect the rat retina from AMPA-induced neurotoxicity. **Investigative Ophthalmology Visual Science** 49:3080**-**3089**,**  2008.  
53. Marazioti, A., Pitychoutis, P.M., Papadopoulou-Daifoti, Z., Spyraki, C., **Thermos, K.**\*Activation of **s**omatostatin receptor in the globus pallidus increases rat locomotor activity and dopamine levels in the striatum **Psychopharmacology** 201:413-422, 2008.   
54. Santis, S., Kastellakis, A., Kotzamani, D., Pitarokoili,K., Kokona, D., and **Thermos, K.** \* Somatostatin increases rat locomotor activity by activating sst2 and sst4 receptors in the striatum and via glutamatergic involvement. **Naunyn-Schmiedeberg Archives of Pharmacology** 379:181-189,2009.   
55. Pallis, E., Vasilaki A., Fehlmann, D., Kastellakis A., Hoyer, D., Spyraki, C. and **Thermos, K.**\* Acute and chronic administration of citalopram influences somatostatin levels and somatostatin receptor pharmacology in brain.  **Neuropsychopharmacology** 34: 952-963, 2009.  
56. Vasilaki, A. and **Thermos, K\*.** [Somatostatin analogues as therapeutics in retinal disease.](http://www.ncbi.nlm.nih.gov/pubmed/19351548?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) **Pharmacology and Therapeutics** 122:324-333, 2009  
57. Marazioti, A., Spyraki, C., **Thermos, K.** \*GABA antagonists reverse the somatostatin dependent attenuation of rat locomotor activity. **Neuropeptides** 43:207-12, 2009.   
58. Kiagiadaki, F., Savvaki, M., **Thermos, K.** \*Activation of somatostatin receptor (sst5) protects the rat retina from AMPA-induced neurotoxicity. **Neuropharmacology** 58:297-303, 2010  
59.De Bundel, D., Aourz N., Kiagiadaki F., Clinckers R., Hoyer, D., Kastellakis, A., Michotte, Y., **Thermos, K.,** Smolders, I.Hippocampal somatostatin sst1 receptors act as autoreceptors but are not required for the anticonvulsant action of somatostatin in rats. **Neuroreport**  21:254-258, 2010.  
60. Papadaki, T., Tsilimbaris, M., Pallikaris I., **Thermos, K\*.** Somatostatin receptor activation influences human retinal pigment epithelium cell viability. **Acta Opththalmologica**, 88:e228-233, 2010.   
61. Kokona, D., Charalampopoulos I., Pediaditakis, I., Gravanis, A., Thermos, K\*. The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA induced excitotoxicity: NGF TrkA receptor involvement" **Neuropharmacology**, 62:2106-17, 2012.  
62. Kokona, D., Mastrodimou, N., Pediaditakis, I., Charalampopoulos I., Schmid, H.A., **Thermos, K\*.** Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies. Experimental Eye Research, 103:90-98, 2012.   
63. Gravanis, A., Calogeropoulou. T., Panoutsakopoulou, V., **Thermos, K.,**  Neophytou, C., Charalampopoulos, I. Microneurotrophins: Neurosteroids bind to NGF receptors, inducing pro- survival signaling in neuronal cells, **Science Signalling**, 5:pt8.2012.  
64. [Ayiomamitis G](https://www.researchgate.net/researcher/38819665_Ayiomamitis_G), [George Notas](https://www.researchgate.net/researcher/39434472_George_Notas), [Apostolos Zaravinos](https://www.researchgate.net/researcher/38360254_Apostolos_Zaravinos), [Ioannis Drygiannakis](https://www.researchgate.net/researcher/38673894_Ioannis_Drygiannakis), [Maria Georgiadou](https://www.researchgate.net/researcher/69512075_Maria_Georgiadou), [Ourania Sfakianaki](https://www.researchgate.net/researcher/48585602_Ourania_Sfakianaki), [Niki Mastrodimou](https://www.researchgate.net/researcher/38657151_Niki_Mastrodimou), [**Kyriaki Thermos**](https://www.researchgate.net/researcher/39044594_Kyriaki_Thermos)**,** Kouroumalis E. [Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity](https://www.researchgate.net/publication/267507863_Effects_of_octreotide_and_insulin_on_colon_cancer_cellular_proliferation_and_correlation_with_hTERT_activity?ev=auth_pub) **Oncoscience.** 1:457-467, 2014**.   
65.** Kokona D. **&** Thermos K. \***,** Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways. [Experimental Eye Research,](http://www.ncbi.nlm.nih.gov/pubmed/25989217)136:45-58, 2015**.**  
66. De Bundel D, Fafouri A, Csaba Z, Loyens E, Lebon S, El Ghouzzi V, Peineau S, Vodjdani G, Kiagiadaki F, Aourz N, Coppens J, Walrave L, Portelli J, Vanderheyden P, Chai SY, **Thermos K**, Bernard V, Collingridge G, Auvin S, Gressens P, Smolders I, Dournaud P. Trans-modulation of the somatostatin type 2A receptor trafficking by Insulin-regulated aminopeptidase decreases limbic seizures. **J. Neuroscience** 35:11960-75, 2015.  
67. Kalomiraki, Μ., **Thermos, K**., Chaniotakis, N.A. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications, **International Journal of Nanomedicine,** 10: 1–12, 2015.  
68. Kokona, D., Georgiou, P-C., Kounenidakis, M., Kiagiadaki, F. and **K Thermos K.**\* Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease. **Neural Plasticity**, Special Issue on “Cannabinoids in the Brain: New Vistas on an old dilemma”, doi:10.1155/2016/8373020., 2016.   
69. Ibán-Arias, R., Lisa, S., Mastrodimou, N., Kokona, D., Koulakis, E., Iordanidou, P., Kouvarakis, A., Fothiadaki, M., Papadogkonaki, S., Sotiriou, A., Katerinopoulos, H.E., Gravanis, A., Charalampopoulos, I., **Thermos, K\***. [The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes.](https://www.ncbi.nlm.nih.gov/pubmed/29208634) **Diabetes** 67:321-333, 2018.  
70. Papadogkonaki S., Theodorakis K, **Thermos K\*.** (2019) Endogenous and synthetic cannabinoids induce the downregulation of cannabinoid CB1 receptor in retina. **Experimental Eye Research**  185:107694.  
 doi: 10.1016/j.exer.2019.  
71. Iban-Arias, R., Lisa, S., Poulaki, S., Mastrodimou, N., Charalampopoulos, I., Gravanis, A., **Thermos, K.\*** Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina. **Graefe's Archives for Clinical and Experimental Ophthalmology** 257:2429-2436, 2019.

72.  Katsidoni V, Tzatzarakis MN, Karzi V, **Thermos K**, Kastellakis A, Panagis G. [Differential effects of chronic voluntary wheel-running on morphine induced brain stimulation reward, motor activity and striatal dopaminergic activity.](https://pubmed.ncbi.nlm.nih.gov/32721470/) **Behav Brain Res.** 394:112831. 2020. doi: 10.1016/j.bbr.2020.112831.

73. Dionysopoulou S, Wikström P, Walum E, **Thermos K\*.** [Effect of NADPH oxidase inhibitors in an experimental retinal model of excitotoxicity.](https://pubmed.ncbi.nlm.nih.gov/32916159/)Exp Eye Res. 200:108232. 2020. doi: 10.1016/j.exer.2020.108232.

74. Spyridakos D, Papadogkonaki S, Dionysopoulou S, Mastrodimou N, Polioudaki H, **Thermos K\***. [Effect of acute and subchronic administration of (R)-WIN55,212-2 induced neuroprotection and anti inflammatory actions in rat retina: CB1 and CB2 receptor involvement.](https://pubmed.ncbi.nlm.nih.gov/33220388/) Neurochem Int.. 142:104907.2021. doi:10.1016/j.neuint.2020.104907.

75.Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS, **Thermos K\*.** [The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.](https://pubmed.ncbi.nlm.nih.gov/33450278/) Neuropharmacology. 185:108450. 2021. doi: 10.1016/j.neuropharm.2021.108450.

**Invited talks (selected)**

1990 “Characterization of somatostatin receptors in brain. Universite de Marseille, Faculte des Sciences de Saint Jerome.  
1998 "Somatostatin's Importance in the Basal Ganglia: an in vivo micro-dialysis study" MERCK Research Laboratories, New Jersey, USA  
1998 "Somatostatin's Importance in the Basal Ganglia: an in vivo microdialysis study", University of Sussex  
2000"Somatostatin's role in the Basal Ganglia", University of Edinburgh, UK  
2000 "Somatostatin and its receptors: molecular biology to therapeutics" 6th World Hellenic Biomedical Congress, Athens   
2002 "Functional Mapping of Somatostatin receptors in the retina"22nd Blankanese Conference, Hamburg- Blankanese, Germany  
2004 Protective effects of somatostatin analogs against chemically ιnduced ischemia in rat retina: role of somatostatin in the treatment of retinopathies”, 5th Conference Medicinal Chemistry: Drug Discovery and Design, Patras   
2009 Somatostatin analogs as therapeutics in retinal disease. Aegean Retina XI Chania, July 3-5, 2009  
2009 Nitric oxide and cGMP protect the retinal from ischemia and mediate somatostatin’s neuroprotective effects. European Association of Vision and Eye Research (EVER), Portoroz, Slovenia, September 30-October 3, 2009.  
2010 Immunohistochemistry and Western blot methodologies to evaluate neuroprotective agents in models of retinopathies. European Association of Vision and Eye Research (EVER), Hersonisos, Crete, October 6-9, 2010  
2011 Somatostatin analogues as therapeutics in ischemia induced retinopathies. Summer Neuropeptide Conference and The European Neuropeptide Club (ENC) Meeting, May 22 - 25, [Boston, MA, USA,](http://cambridge.hyatt.com/hyatt/hotels/index.jsp) 2011.  
2013 The novel neurosteroid DHEA spiro-epoxy derivative, BNN27, provides neuroprotection to the retina when administered in drops and intra-peritoneally in the STZ-model of Diabetic Retinopathy. Agean Retina Meeting, Santorini, 2013.

***Reviewer for International Journals and Grant Agencies***

Brain Research, Brain Research Bulletin, Current Eye Research, European Journal Neuroscience, Investigative Ophthalmology and Visual Science (IOVS), Journal of Chemical Neuroanatomy, Journal of Neurochemistry, Life Science, Molecular Cellular Endocrinology, Molecular Vision, Naunyn-Schmiedeberg's Archives of Pharmacology, Neuropeptides, Neuropharmacology, Neuroscience, Neuroscience Letters, Pharmacology, Biochemistry and Behavior, Pharmacology and Therapeutics, The Asia-Pacific Journal of Endocrinology, Vision Research, Visual Neuroscience.

Dr. Thermos also served as reviewer of grant proposals/study sections: National Science Foundation (USA), Neuroscience Study Section, European Commission, Brussels, ITN & Marie-Curie Programs, Brussels, and Greek Ministry of Health, Human Brain Project, Brussels, AXA-SW.